Publications by authors named "Ron Wolf"
Article Synopsis
- - The study investigated the impact of neoadjuvant therapy (NAT) on the surgical outcomes of gallbladder cancer patients, hypothesizing similar postoperative complications compared to those who didn't receive NAT.
- - Data from a national database was analyzed, matching 37 patients who received NAT with 74 patients who did not, and findings showed no significant differences in bile leakage, liver failure, readmission, or mortality rates between the groups.
- - However, patients undergoing NAT had a higher incidence of blood transfusions, indicating a potential risk factor; the authors recommend further research to validate these initial findings due to possible limitations in the study's power.
Background: Hepatocellular carcinoma arises in an environment of chronic injury, and wound-healing responses may vary by treatment.
Methods: Peripheral blood myeloid populations were quantified in 39 patients with hepatocellular carcinoma treated with surgical or endoluminal therapy. Macrophages were quantified in tissue when available.
Purpose: To evaluate neoadjuvant therapy with weekly paclitaxel/carboplatin plus 5-fluorouracil (5-FU) with conformal radiotherapy in a phase II trial in resectable esophageal carcinoma.
Methods: Twenty-four patients with T2-4N0-1M0-1a esophageal carcinoma were treated with paclitaxel 45 mg/m(2) intravenously over 1 hour and carboplatin at an area under the concentration-time curve (AUC) of 2 intravenously over 30 minutes on days 1, 8, 15, 22, and 29. 5-Fluorouracil 225 mg/m(2) was delivered as a continuous infusion on days 1-33.